The latest price target for BioCardia (NASDAQ:BCDA) was reported by HC Wainwright & Co. on November 14, 2024. The analyst firm set a price target for $25.00 expecting BCDA to rise to within 12 months (a possible 1143.78% upside). 6 analyst firms have reported ratings in the last year.

The latest analyst rating for BioCardia (NASDAQ:BCDA) was provided by HC Wainwright & Co., and BioCardia reiterated their buy rating.

There is no last upgrade for BioCardia

The last downgrade for BioCardia Inc happened on November 11, 2022 when Dawson James changed their price target from N/A to N/A for BioCardia Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioCardia, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioCardia was filed on November 14, 2024 so you should expect the next rating to be made available sometime around November 14, 2025.

While ratings are subjective and will change, the latest BioCardia (BCDA) rating was a reiterated with a price target of $25.00 to $25.00. The current price BioCardia (BCDA) is trading at is $2.01, which is out of the analyst’s predicted range.